- Home
- QNST vs PHAT Comparison
QNST vs PHAT Comparison
Compare QNST & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNST | PHAT |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 792.3M | 942.6M |
| IPO Year | 2010 | 2019 |
Fundamental Metrics
Financial Performance| Metric | QNST | PHAT |
|---|---|---|
| Price | $14.74 | $14.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $26.40 | $17.33 |
| AVG Volume (30 Days) | 557.1K | ★ 809.7K |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $1,100,345,000.00 | $147,190,000.00 |
| Revenue This Year | $11.73 | $218.59 |
| Revenue Next Year | $9.82 | $84.38 |
| P/E Ratio | $81.67 | ★ N/A |
| Revenue Growth | 43.12 | ★ 460.30 |
| 52 Week Low | $12.98 | $2.21 |
| 52 Week High | $25.50 | $16.45 |
Technical Indicators
Market Signals| Indicator | QNST | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 53.01 |
| Support Level | $14.45 | $14.12 |
| Resistance Level | $14.79 | $16.45 |
| Average True Range (ATR) | 0.46 | 0.73 |
| MACD | 0.09 | -0.11 |
| Stochastic Oscillator | 57.48 | 21.67 |
Price Performance
Historical ComparisonAbout QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia. Geographically, it operates in United States and Internationally, of which maximum revenue is derived from United States.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.